Relapsed Or Refractory Hematologic Malignancies clinical trials

Explore recruiting relapsed or refractory hematologic malignancies clinical trials.

Recruiting relapsed or refractory hematologic malignancies studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Or Refractory Hematologic Malignancies trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

Hungary, Spain, Czechia, Sweden, Denmark, Greece +1 more

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

PHASE I STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE FOR TRICHOSTATIN A IN SUBJECTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES

Poland

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Relapsed Or Refractory Hematologic Malignancies trials by city

Relapsed Or Refractory Hematologic Malignancies in Toronto Relapsed Or Refractory Hematologic Malignancies in Vancouver Relapsed Or Refractory Hematologic Malignancies in Montreal Relapsed Or Refractory Hematologic Malignancies in Calgary Relapsed Or Refractory Hematologic Malignancies in Edmonton Relapsed Or Refractory Hematologic Malignancies in Ottawa Relapsed Or Refractory Hematologic Malignancies in Winnipeg Relapsed Or Refractory Hematologic Malignancies in Quebec City Relapsed Or Refractory Hematologic Malignancies in Hamilton Relapsed Or Refractory Hematologic Malignancies in Kitchener Relapsed Or Refractory Hematologic Malignancies in London Relapsed Or Refractory Hematologic Malignancies in Halifax Relapsed Or Refractory Hematologic Malignancies in New York Relapsed Or Refractory Hematologic Malignancies in Los Angeles Relapsed Or Refractory Hematologic Malignancies in Chicago Relapsed Or Refractory Hematologic Malignancies in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease